Gamida Cell Bounces Back With Omisirge US Approval
For Use In Hematological Malignancies
The Israeli firm Gamida Cell’s lead candidate has obtained a US approval as a new donor source for allogeneic stem cell transplant with the chips in place for independent commercialization despite its recent financial troubles.
